Gyre Therapeutics Inc. Cash Flow Quality Index
Gyre Therapeutics Inc. cash flow quality index. Gyre Therapeutics Inc. (GYRE) has a Cash Flow Quality Index of 0.79x as of September 2025. Operating cash flow of $4.68 Million is below net income of $5.94 Million, suggesting accrual-heavy earnings not yet converted to cash. See Gyre Therapeutics Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Gyre Therapeutics Inc. (2006–2025)
Cash flow quality index of Gyre Therapeutics Inc. from 2006 to 2025. Historical Cash Flow Quality Index for Gyre Therapeutics Inc. across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore cash flow to debt ratio of Gyre Therapeutics Inc. to assess how comfortably operating cash covers total debt obligations.
Gyre Therapeutics Inc. Cash Flow Quality Index by Year (2006–2025)
Gyre Therapeutics Inc. cash flow quality index by year from 2006 to 2025. Year-by-year earnings quality comparison for Gyre Therapeutics Inc.. For the full cash flow conversion analysis, see Gyre Therapeutics Inc. (GYRE) cash conversion ratio.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | $1.01 Million | $9.88 Million | ▲ +150.3% |
| 2024 | -0.20x | $-3.64 Million | $17.90 Million | ▼ -108.2% |
| 2022 | 2.47x | $10.68 Million | $4.31 Million | ▼ -80.5% |
| 2010 | 12.69x | $138.30 Million | $10.90 Million | ▲ +368.9% |
| 2006 | -4.72x | $-9.89 Million | $2.10 Million | — |